Shilpa Medicare’s arm, SteinCares enter into strategic licensing agreement

24 Feb 2026 Evaluate

Shilpa Medicare’s subsidiary -- Shilpa Biologicals and SteinCares have entered into strategic licensing agreement to commercialize a biosimilar across Latin America. Under the agreement, SteinCares will hold exclusive rights to register, commercialize, and distribute the biosimilar across the region while Shilpa Biologicals will complete product development and provide long-term commercial manufacturing from its facility in Dharwad, India.

The partnership brings together Shilpa Biologicals’ expertise in biologics development and highquality commercial manufacturing with SteinCares’ integrated regional platform, combining regulatory capabilities, market access, and deep understanding of Latin American healthcare systems. This partnership builds on SteinCares' track record of successfully introducing biosimilars in the region, and strengthens its specialty care portfolio, empowering patients with safe and cost effective treatments across Latin America.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

332.40 9.40 (2.91%)
06-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1798.95
Dr. Reddys Lab 1303.90
Cipla 1321.75
Zydus Lifesciences 912.95
Lupin 2344.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×